Company intelligence / Profile preview

SolaranRx

Albuquerque, New Mexico, United Statesinsights.citeline.com ↗

Ownership: Private
Development stage: Other

Overview

SolaranRx developed a proprietary peptide-based theranostic platform targeting the melanocortin 1 receptor, over-expressed in ~80% of metastatic melanoma. Their lead compound, SRX‑1177, showed proof-of-concept in mouse models and was selected as a top oncology project to watch. The company entered into a CRADA with the National Cancer Institute for further preclinical evaluation but is now out of business.

Therapeutic areas: Oncology
Modalities: PeptidesRadiopharmaceuticalCompanion imaging agent (diagnostic peptide)
Industry: Biotech

Drug pipeline

1 asset

SRX-1177

Preclinical

Partnerships

National Cancer Institute/NIH Cooperative Research and Development Agreement for preclinical studies on metastatic melanoma theranostics

Beyond the preview

Go deeper on SolaranRx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SolaranRx.

Explore the full profile